Cargando…

Intravascular Large B-cell lymphoma: A case series and review of literatures

BACKGROUND: Intravascular large B-cell lymphoma (IVLBCL) is a rare subtype of non-Hodgkin lymphoma with uncommon clinical presentations and poor prognosis. The purpose of this study is to report the clinical features and outcome of IVLBCL in a single institution of Taiwan. METHODS: Ten patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Ong, Yuen-Chin, Kao, Hsiao-Wen, Chuang, Wen-Yu, Hung, Yu-Shin, Lin, Tung-Liang, Chang, Hung, Kuo, Ming-Chung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chang Gung University 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514799/
https://www.ncbi.nlm.nih.gov/pubmed/32344119
http://dx.doi.org/10.1016/j.bj.2020.04.005
_version_ 1784583473067982848
author Ong, Yuen-Chin
Kao, Hsiao-Wen
Chuang, Wen-Yu
Hung, Yu-Shin
Lin, Tung-Liang
Chang, Hung
Kuo, Ming-Chung
author_facet Ong, Yuen-Chin
Kao, Hsiao-Wen
Chuang, Wen-Yu
Hung, Yu-Shin
Lin, Tung-Liang
Chang, Hung
Kuo, Ming-Chung
author_sort Ong, Yuen-Chin
collection PubMed
description BACKGROUND: Intravascular large B-cell lymphoma (IVLBCL) is a rare subtype of non-Hodgkin lymphoma with uncommon clinical presentations and poor prognosis. The purpose of this study is to report the clinical features and outcome of IVLBCL in a single institution of Taiwan. METHODS: Ten patients with IVLBCL diagnosed from June 2006 to January 2018 were retrospectively reviewed. RESULTS: The median age was 61 (range 39–88) years. The most common presentation was fever (90%), cytopenia (90%), and confusion (50%). For all patients, the median progression free survival (PFS) and overall survival (OS) were 12.6 (95% confidence interval [CI] 0.0–76.1) and 18.8 (95% CI 0–59.3) months, respectively. Six patients received rituximab combined chemotherapy, and the other one patient was treated with chemotherapy alone. Six of seven (85.7%) patients achieved complete response after chemotherapy. The median PFS and OS for six patients who completed treatment were not reached. Three-year PFS and OS rates were 80% and 75%, respectively. CONCLUSION: Our study showed that patients might achieve durable remission after rituximab-based chemotherapy. The outcome of IVLBCL patients may further improve if early diagnosis and prompt treatment were made.
format Online
Article
Text
id pubmed-8514799
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Chang Gung University
record_format MEDLINE/PubMed
spelling pubmed-85147992021-10-21 Intravascular Large B-cell lymphoma: A case series and review of literatures Ong, Yuen-Chin Kao, Hsiao-Wen Chuang, Wen-Yu Hung, Yu-Shin Lin, Tung-Liang Chang, Hung Kuo, Ming-Chung Biomed J Original Article BACKGROUND: Intravascular large B-cell lymphoma (IVLBCL) is a rare subtype of non-Hodgkin lymphoma with uncommon clinical presentations and poor prognosis. The purpose of this study is to report the clinical features and outcome of IVLBCL in a single institution of Taiwan. METHODS: Ten patients with IVLBCL diagnosed from June 2006 to January 2018 were retrospectively reviewed. RESULTS: The median age was 61 (range 39–88) years. The most common presentation was fever (90%), cytopenia (90%), and confusion (50%). For all patients, the median progression free survival (PFS) and overall survival (OS) were 12.6 (95% confidence interval [CI] 0.0–76.1) and 18.8 (95% CI 0–59.3) months, respectively. Six patients received rituximab combined chemotherapy, and the other one patient was treated with chemotherapy alone. Six of seven (85.7%) patients achieved complete response after chemotherapy. The median PFS and OS for six patients who completed treatment were not reached. Three-year PFS and OS rates were 80% and 75%, respectively. CONCLUSION: Our study showed that patients might achieve durable remission after rituximab-based chemotherapy. The outcome of IVLBCL patients may further improve if early diagnosis and prompt treatment were made. Chang Gung University 2021-08 2020-04-25 /pmc/articles/PMC8514799/ /pubmed/32344119 http://dx.doi.org/10.1016/j.bj.2020.04.005 Text en © 2020 Chang Gung University. Publishing services by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Ong, Yuen-Chin
Kao, Hsiao-Wen
Chuang, Wen-Yu
Hung, Yu-Shin
Lin, Tung-Liang
Chang, Hung
Kuo, Ming-Chung
Intravascular Large B-cell lymphoma: A case series and review of literatures
title Intravascular Large B-cell lymphoma: A case series and review of literatures
title_full Intravascular Large B-cell lymphoma: A case series and review of literatures
title_fullStr Intravascular Large B-cell lymphoma: A case series and review of literatures
title_full_unstemmed Intravascular Large B-cell lymphoma: A case series and review of literatures
title_short Intravascular Large B-cell lymphoma: A case series and review of literatures
title_sort intravascular large b-cell lymphoma: a case series and review of literatures
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514799/
https://www.ncbi.nlm.nih.gov/pubmed/32344119
http://dx.doi.org/10.1016/j.bj.2020.04.005
work_keys_str_mv AT ongyuenchin intravascularlargebcelllymphomaacaseseriesandreviewofliteratures
AT kaohsiaowen intravascularlargebcelllymphomaacaseseriesandreviewofliteratures
AT chuangwenyu intravascularlargebcelllymphomaacaseseriesandreviewofliteratures
AT hungyushin intravascularlargebcelllymphomaacaseseriesandreviewofliteratures
AT lintungliang intravascularlargebcelllymphomaacaseseriesandreviewofliteratures
AT changhung intravascularlargebcelllymphomaacaseseriesandreviewofliteratures
AT kuomingchung intravascularlargebcelllymphomaacaseseriesandreviewofliteratures